Home > Newsletters > International Pharmaceutical Regulatory Monitor > Emerging Markets Encouraged to Focus on Most Likely Counterfeits
International Pharmaceutical Regulatory Monitor
June 2012 | Vol. 40 No. 6
Emerging Markets Encouraged to Focus on Most Likely Counterfeits
Drugmakers breaking into emerging markets could see supply chain benefits and quicker product launches if these markets automatically registered U.S. Food and Drug Administration (FDA)-approved products before testing for quality issues, according to a new study.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.